Tag Archives: Isavuconazole

Basilea to receive sales milestone payments from Astellas based on exceeding certain thresholds from the sales of antifungal Cresemba®

Posted on 11, December 2018 by

BASEL, 11-Dec-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba® (isavuconazole) by Astellas Pharma Inc. (“Astellas”) in the United States exceeded the threshold triggering a milestone payment to Basilea in the amount of … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , , , , ,

U.S. FDA designated Basilea Pharmaceutica’s isavuconazole as Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis

Posted on 11, December 2013 by

Basel, Switzerland, 11-12-2013 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis. QIDP status provides priority review and … Read the full press release →

Posted in Government, Healthcare, Pharma & Biotech, Switzerland

Tagged , , , , , , , , , , , ,

Basilea announced improved operating results in its H1-2013 financials

Posted on 22, August 2013 by

Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data and ceftobiprole regulatory decision in Europe maintained for H2 2013 Significant agreement with BARDA of up to USD 89 million … Read the full press release →

Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, Switzerland

Tagged , , , , , , , , , , , , , , , , , ,